A Director at Vical Inc (NASDAQ: VICL) is Buying Shares

By Carrie Williams

Yesterday, a Director at Vical Inc (NASDAQ: VICL), Robert Merton, bought shares of VICL for $150K.

Following this transaction Robert Merton’s holding in the company was increased by 878.88% to a total of $181.4K.

Based on Vical Inc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $3.24 million and GAAP net loss of $3.09 million. In comparison, last year the company earned revenue of $2.64 million and had a GAAP net loss of $2.52 million. The company has a one-year high of $3.70 and a one-year low of $1.66. Currently, Vical Inc has an average volume of 402.9K.

Seven different firms, including Barclays and Canaccord Genuity, currently also have a Buy rating on the stock. Starting in July 2016, VICL received 6 Buy ratings in a row.

Robert Merton’s trades have generated a -16.6% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vical, Inc. is a biopharmaceutical company. The company engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.